Skip to main content

Table 1 Individual clinical and immunohistochemical markers for the prediction of early versus late recurrence in transATAC

From: Markers for the identification of late breast cancer recurrence

 

0-5 years

5-10 years

(number of all recurrences = 83)

(number of all recurrences = 107)

 

Univariate

Multivariate

Univariate

Multivariate

 

LR-χ2

LR-χ2a

LR-χ2

LR-χ2a

(P value)

(P value)

(P value)

(P value)

Nodal status (negative versus positive)

17.24

7.60

30.80

18.99

(<0.0001)

(0.006)

(<0.0001)

(<0.0001)

Tumor size (≤2 versus >2 cm)

28.95

10.96

25.40

13.03

(<0.0001)

(0.0009)

(<0.0001)

(0.0003)

Grade (well/moderate versus poor)

21.88

5.22

1.74

-

(<0.0001)

(0.02)

(0.2)

ER10

12.17

5.51

1.65

-

(0.004)

(0.02)

(0.2)

PgR10

18.81

6.46

1.45

-

(<0.0001)

(0.01)

(0.2)

Ki67

17.90

6.52

9.04

2.14

(<0.0001)

(0.01)

(0.003)

(0.1)

HER2 (negative versus positive)

15.45

3.18

0.04

-

(<0.0001)

(0.07)

(0.8)

  1. aFor addition to model containing all other factors that were significant in the univariate model. ATAC, Arimidex, Tamoxifen, Alone or in Combination; ER, estrogen receptor; HER2, human epidermal growth factor; LR, likelihood ratio; PgR, progesterone receptor. Table was adapted from [9].